Webinar: ACR/CHEST ILD Guidelines in Practice| Video: COVID in the Rear View

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Conditions

Subcategories:Axial SpondyloarthritisGout and Crystalline ArthritisGuidelinesMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

Unclear If Sports Raise Later Arthritis Risk

Carolyn Crist  |  

(Reuters Health)—Playing team sports, especially soccer, at the elite level may lead to a higher risk for osteoarthritis, but the existing research is of such low quality it’s hard to say for sure, according to a recent review. In an analysis of past studies filled with conflicting results, researchers found that long-distance running was the…

Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout

  |  

We read the case report by Dr. Diana Girnita and colleagues (“Severe Refractory Gout: What options are left when pegloticase fails?” The Rheumatologist, August 2016) with interest. A case is reported of a subject with 20 years of chronic refractory gout who failed to respond to pegloticase therapy, and the potential roles of anti-drug antibodies or…

Mechanistic, Epidemiologic Clues Suggest Possible Link Between Obesity, Inflammation in Rheumatoid Arthritis

  |  

Obesity has an established systemic inflammatory component. Could that be a trigger for the inflammation seen in rheumatoid arthritis (RA) and other rheumatic diseases? Although there is no direct scientific evidence, both mechanistic and epidemiologic clues do give some intriguing suggestions of a possible link. “At first, we thought that fat was involved only in…

Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention

Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention

  |  

Established wisdom holds that patients with rheumatoid arthritis (RA) will fare better if their disease is diagnosed as early as possible, and treatments with disease-modifying drugs are started before inflammation can do more damage to joints and tissue. Usually, early diagnosis means spotting the clinical signs of disease, but new research tells us more about…

Targeted Therapy for Scleroderma Fibrosis

Sara R. Schoenfeld, MD, & Flavia V. Castelino, MD  |  

Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

Rheumatology Drug Updates: Abaloparatide Promising for Osteoporosis, Plus Secukinumab for Ankylosing Spondylitis

  |  

Abaloparatide for Osteoporosis Abaloparatide is completing Phase III clinical trials for the potential treatment of postmenopausal osteoporosis in women who are at an increased risk of fracture.1 Abaloparatide is a synthetic peptide that engages the parathyroid hormone receptor and has favorable bone building activity. Abaloparatide has completed Phase 3 development for use as a daily…

New Large-Vessel Vasculitis Therapies Emerge, but Better Options Still Needed

  |  

LONDON—New therapies are emerging for the two main forms of large-vessel vasculitis, giant cell arteritis (GCA) and Takayasu’s arteritis—particularly biologic therapies. But for just about every available treatment gap, drawbacks or limited evidence remain, with the results needing to be borne out in larger trials, an expert said at the Annual Congress of the European…